Gimme Care Review: What Its Compounded GLP-1 Program Documents—and What It Does Not Prove

Gimme Care’s most important evidence statement is not a weight-loss promise. It is the disclosure that its compounded formulations have not undergone clinical trials evaluating their safety, effectiveness or therapeutic equivalence to FDA-approved medicines. That distinction shapes this review: a website can document prices, access and refund procedures without establishing how well its particular preparations work. Gimme offers a recognizable online care pathway, but the evidence supporting that pathway needs to be separated from evidence supporting a medicine studied elsewhere.

The public documentation consulted October 19, 2026 describes compounded injectable semaglutide and tirzepatide, clinician review, home shipping and portal-based follow-up. It also identifies separate platform and telehealth responsibilities, cash-pay terms and a conditional four-month satisfaction policy. This review examines what those documents establish, what remains unresolved and which questions are worth answering before enrollment. It does not verify professional licenses, pharmacy operations or patient outcomes, and it does not treat advertised access as a guaranteed prescription.

At a glance

Documented GLP-1 offerings: Gimme advertises compounded semaglutide and compounded tirzepatide as once-weekly subcutaneous injections, subject to a prescription after clinical review.
Sources: [9] [8]
Published monthly price equivalents: Semaglutide is listed at $160, $130 or $119 per month for one-, three- or six-month cycles; tirzepatide is $199, $163 or $149, respectively. Complete upfront-payment terms are not established.
Sources: [9] [8]
Formulation evidence: Gimme states that its compounded formulations are not FDA approved and have not undergone trials evaluating safety, efficacy or therapeutic equivalence to FDA-approved medicines.
Sources: [6]
Separate service responsibilities: Start Gimme, LLC operates the platform; the terms identify Bask Telehealth LLC as the telehealth channel. Gimme says it neither directly provides medical services nor operates as a pharmacy.
Sources: [5] [9]
Conditional satisfaction policy: The Progress Promise requires four consecutive months, an initial weight-verification video and a timely claim. It is not an unconditional refund or a guarantee of weight loss.
Sources: [5]

Start with the formulation disclosure, not the marketing

Gimme’s product pages identify two compounded GLP-1 offerings: semaglutide and tirzepatide, both described as once-weekly subcutaneous injections. Those descriptions establish the advertised route, not an oral or sublingual alternative. Gimme also says it sources compounded GLP-1 medicines exclusively from U.S. pharmacies. That is a provider statement, not an independent verification of the pharmacies, their licenses or the preparations they dispense.

The website’s footer makes a consequential qualification: its formulations have not undergone clinical trials evaluating safety, efficacy or therapeutic equivalence to FDA-approved medications. This is more specific than a general compounding disclaimer. It means a reader should not interpret familiar ingredient names, testimonials or references to approved products as evidence that Gimme’s exact preparations have demonstrated the same outcomes. The consulted documentation does not establish their additional ingredients, concentrations or actual dispensed presentations.

FDA explains that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not prove clinical inequivalence or establish that a provider is good or bad. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our guide to approved medicines and compounded preparations explains why these are separate evidence questions.

Sources: [9] [8] [6] [1]

The company, clinician and pharmacy are different actors

The terms identify Start Gimme, LLC, doing business as Gimme Care, and its affiliates as the website operators. They explicitly say Gimme does not provide medical services. Instead, medical services come through a contracted network of healthcare providers described as licensed in the patient’s state of residence. A separate provision says telehealth services are provided through Bask Telehealth LLC. These distinctions matter because the brand collecting an enrollment is not necessarily the entity making a clinical decision.

Bask’s published mailing address is 555 Madison Ave., Suite 1202, New York, NY 10022. Gimme separately states that it is not a pharmacy and connects patients with licensed healthcare professionals who determine treatment eligibility. A prescription depends on review of a medical questionnaire and medical appropriateness. The documentation therefore supports a platform-and-network model, not a claim that every interaction is with a physician or that submitting payment guarantees access to medication.

The dispensing side is less transparent. The consulted pages do not name the pharmacies, establish their regulatory classifications or show which pharmacy serves each treatment and location. Before enrolling, a useful request is the prospective dispenser’s identity and contact information, alongside the clinician’s identity and credentials. Those details would make it easier to direct prescription questions, shipment concerns and formulation questions to the responsible party rather than assuming Gimme handles every step itself.

Sources: [5] [9]

Published prices are concrete; the full payment schedule is not

Gimme lists different monthly amounts for one-, three- and six-month billing cycles. The table preserves the advertised product and route rather than treating all GLP-1 plans as interchangeable. These listings are not described as introductory prices in the consulted product blocks. However, the monthly equivalents do not, by themselves, establish when every charge is collected, how much medication arrives at once or whether a plan duration represents a minimum commitment.

The homepage provides one additional billing detail: its $130-per-month three-month plan is billed every three months, compared with $160 for month-to-month service. That answer does not name the medicine, although its figures match the semaglutide page. It should not be applied to tirzepatide. Complete upfront-payment terms, six-month collection arrangements, renewal pricing, price-change provisions and handling of unused balances remain unresolved in the consulted documentation.

The tirzepatide page says its price includes consultation, care, medication, supplies, shipping and support, with the same price at every dose and no membership or hidden fees. The homepage similarly describes a bundled price. Laboratory testing and outside services are not clearly addressed. The terms also go beyond “no insurance required”: Gimme and the providers do not accept commercial insurance, are not in commercial networks and are not enrolled in Medicare or Medicaid. The service is cash-pay.

Advertised compounded injection plans; monthly equivalents are not complete collection schedules
Product and route	Advertised billing cycle	Listed price per month
Compounded semaglutide, subcutaneous injection	One month	$160
Compounded semaglutide, subcutaneous injection	Three months / six months	$130 / $119
Compounded tirzepatide, subcutaneous injection	One month	$199
Compounded tirzepatide, subcutaneous injection	Three months / six months	$163 / $149

Sources: [9] [8] [6] [5]

Enrollment begins online, but access still depends on review

The advertised entry point is an online questionnaire about health and goals, reviewed by a licensed provider. Gimme says services are available in all 50 states and the District of Columbia. That is a geographic access claim, not confirmation that every person can obtain every product. The consulted pages do not establish product-specific BMI thresholds, comorbidity requirements, a complete exclusion list or mandatory laboratory testing for these plans.

Gimme says treatment can begin without a video visit in most states, and patients can request one through the portal. It identifies Kansas, Louisiana, Mississippi, New Mexico and West Virginia as requiring a brief video or audio visit before treatment begins. This is a meaningful operational difference for someone comparing questionnaire-based care with a live consultation. No general numerical deadline for clinical review or first prescription is established in the documentation.

The age language deserves a careful reading rather than a simplified eligibility promise. The terms describe an intended audience of adults 18 and older, but the same provision contains parental-consent language for access that violates the age requirement. Some services may be limited to people over 21, with notice. This does not establish clinical eligibility for minors. Adults should also confirm their own product and location requirements rather than relying solely on the nationwide availability statement.

Sources: [6] [5]

Portal access is documented more clearly than response speed

Gimme advertises unlimited provider messaging for questions, follow-ups and adjustments. Its online portal also supports conversations with support, weight tracking, refill management and shipment updates. Those features describe useful channels for ongoing care, but channel availability does not establish how quickly a clinician answers, who handles urgent concerns or whether every message reaches the prescriber directly. The public descriptions do not supply a numerical clinical response-time commitment.

There is also a distinction between broad availability language and published staffing hours. Although the homepage describes support as always available, the refund policy lists support hours of 8 a.m. to 8 p.m. Eastern Time. A portal that accepts messages at any hour is not evidence of continuously staffed clinical care. The terms additionally warn that ordinary text messages and emails are not encrypted and could be intercepted, a relevant consideration when choosing a communication channel.

NIDDK describes follow-up as a discussion of response and tolerability, not simply continued payment. Gimme’s messaging and short check-ins could support that process, but the documentation does not establish its exact clinical assessment schedule. Our guide to clinical follow-up beyond renewal notices offers a framework for asking what gets reviewed. A practical next question is how the program escalates a concern that cannot be resolved through routine portal messaging.

Sources: [6] [7] [5] [2]

Shipping promises leave important product-handling questions

The homepage says refills are shipped every 28 days after a short check-in, with tracking through the portal. That is a dispatch interval, not a promise of arrival every 28 days or a calendar-month billing definition. Gimme also advertises discreet, free, guaranteed home delivery without a pharmacy visit. The consulted pages do not attach a numerical delivery deadline to that guarantee or establish a general first-shipment or transit timeline.

For damaged or defective deliveries, the policy requires contact within 48 hours of delivery and photographs of the medication and original packaging. If the problem is confirmed, Gimme offers a replacement at no additional cost; a refund is available only if replacement is not possible. For a confirmed wrong medication or incorrect order, it promises to send the correct medication without additional charge and provide return instructions if needed. These are specific remedies, not a general satisfaction return policy.

The documentation does not establish product-specific storage instructions, cold-chain arrangements or procedures for a warm shipment. FDA advises not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. That safety instruction should not be confused with Gimme’s 48-hour commercial reporting window. Our guide to reading delivery and cold-chain claims explains why free shipping and tracking cannot establish appropriate handling.

Sources: [6] [7] [1]

Cancellation and the Progress Promise are separate protections

Products and services are subscriptions unless checkout explicitly identifies a one-time purchase. Subscription details and cancellation options are available through the patient portal. The main order rule permits cancellation before the pharmacy dispenses or ships the medication; either event closes that window. Other wording refers only to shipment, so a dispensed-but-unshipped order deserves clarification. Canceling future service should not be assumed to reverse a charge for an order already dispensed.

The policy says a successfully canceled pre-shipment order receives a full refund within five to ten business days. General refund requests are otherwise limited and not guaranteed: review takes five to seven business days, followed, if approved, by issuance to the original payment method within five to ten business days. Those issuance periods do not guarantee bank receipt. Dispensed or shipped prescription medications cannot be returned, and those medication sales are generally final.

The separate Progress Promise requires a first-time member to remain enrolled for four consecutive months after the initial prescription, follow clinician instructions and keep the account in good standing. Within 14 days of that prescription, the member must submit a continuous, unedited baseline scale video with a visible reading and verbal name and date. Claims are due within 14 days after the four-month mark. Approved refunds remain discretionary, consider participation and incurred costs, and may be issued within 30 days of approval; prior payment disputes exclude additional Promise refunds.

Sources: [7] [5]

Clinical research cannot fill the provider-specific gaps

STEP 1 and SURMOUNT-1 provide randomized evidence about studied subcutaneous semaglutide and tirzepatide regimens in adults with obesity or overweight and related conditions, without diabetes. Neither trial evaluated Gimme Care or its compounded preparations. Their findings cannot establish this program’s outcomes, validate an unidentified pharmacy formulation or predict an individual’s response. Nor does comparing percentages from separate trials create a randomized head-to-head comparison between the medicines or between telehealth providers.

Gimme’s Progress Promise is explicitly a customer satisfaction policy, not insurance, a medical warranty or a guarantee of particular health or weight-loss outcomes. The consulted passages also do not supply a uniform numerical definition of “measurable progress.” Consequently, neither the Promise nor customer testimonials substitute for a defined outcomes study. Our explanation of why a trial is not a company performance report provides the central distinction for interpreting such marketing.

The strongest next evidence would be concrete documentation: the dispensing pharmacy, the prescribed formulation, clear collection and renewal terms, clinical follow-up responsibilities and product-handling instructions. These questions are more useful than assuming either equivalence or inferiority from the word “compounded.” Gimme’s broader storefront also advertises products including sermorelin, NAD+ and glutathione injections, but their presence does not establish evidence for the GLP-1 program or show that combining products improves outcomes.

Sources: [3] [4] [6] [5]

Questions & answers

Does Gimme Care offer FDA-approved GLP-1 products?

The documented plans reviewed here are compounded injectable semaglutide and tirzepatide, not verified offerings of FDA-approved branded products. Gimme itself says its compounded medications are not FDA approved. Approval attaches to a specific drug product, not to a platform, clinician network or pharmacy.

Sources: [9] [8] [1]

Is the $130 monthly price available for tirzepatide?

The product listings place $130 per month under semaglutide’s three-month cycle. Tirzepatide’s three-month listing is $163 per month. The homepage’s general $130 answer does not name the medicine, so it should not override the product-specific tirzepatide pricing or be read as a universal program rate.

Sources: [9] [8] [6]

Can I use insurance to pay Gimme?

The terms describe cash-pay service outside commercial insurance and government programs. They say Gimme and the providers do not accept commercial plans, are not in-network and are not enrolled in Medicare or Medicaid. This is more restrictive than simply saying insurance is unnecessary; it does not establish reimbursement elsewhere.

Sources: [5]

How do I reach support or manage my subscription?

Gimme directs patients to the portal for support conversations, subscription details and cancellation options. Published support hours are 8 a.m. to 8 p.m. Eastern. The consulted text displays masked email addresses, so it does not provide a usable email contact to reproduce here. Confirm a working contact before an urgent order issue arises.

Sources: [6] [7]

Does the four-month Promise guarantee all my money back?

No. It has enrollment, participation, video-verification and claim deadlines. The terms say Gimme may refund the first four months’ payments and that most approved claims receive those amounts in full, but determinations consider participation and incurred costs. It is expressly not a medical warranty or guaranteed weight-loss result.

Sources: [5]

What should I clarify about the medication before the first shipment?

Ask which pharmacy will dispense it, what formulation and presentation are prescribed, what quantity is supplied and which storage instructions apply. Those details are not established in the consulted pages. FDA also warns about measurement and administration errors with compounded medicines; instructions should come from the prescriber or pharmacist, not calculations based on a review.

Sources: [9] [8] [1]

Our assessment

Gimme Care documents a reasonably clear online service outline: two compounded injectable GLP-1 offerings, published plan prices, clinical review, portal follow-up and specific shipment-remedy rules. Its disclosure that the formulations have not undergone clinical trials is important and should remain central to any assessment. The unresolved issues are also material: unnamed dispensing pharmacies, incomplete formulation details, uncertain longer-plan collection terms and limited operational response-time information. The four-month Promise offers conditional commercial recourse, not evidence of effectiveness. A useful next step is to obtain the pharmacy, prescription, billing and follow-up details in writing before treating the advertised bundle as a fully specified care arrangement.

Visit Gimme Care’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Gimme Care Review: What Its Compounded GLP-1 Program Documents—and What It Does Not Prove

At a glance

01Start with the formulation disclosure, not the marketing

02The company, clinician and pharmacy are different actors

03Published prices are concrete; the full payment schedule is not

04Enrollment begins online, but access still depends on review

05Portal access is documented more clearly than response speed

06Shipping promises leave important product-handling questions

07Cancellation and the Progress Promise are separate protections

08Clinical research cannot fill the provider-specific gaps